This analysis evaluates-from a US payer's perspective-the economic impact of using rivaroxaban versus enoxaparin for thromboprophylaxis following total hip or knee replacement surgery.
Samir H. Mody, PharmD, MBA
Advertisement
Articles by Samir H. Mody, PharmD, MBA
Advertisement
Latest Updated Articles
- Economic Model Comparing Rivaroxaban and Enoxaparin for Post-Orthopedic VTE Prophylaxis
Published: June 6th 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
3
Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer
4
FDA Approves Gazyva for Active Lupus Nephritis
5
